Guy MD - Idorsia Ex Officer
| IDIA Stock | CHF 0.84 0.07 9.09% |
Insider
Guy MD is Ex Officer of Idorsia
| Age | 67 |
| Phone | 41 58 844 10 10 |
| Web | https://www.idorsia.com |
Idorsia Management Efficiency
The company has return on total asset (ROA) of (0.4196) % which means that it has lost $0.4196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (64.6068) %, meaning that it generated substantial loss on money invested by shareholders. Idorsia's management efficiency ratios could be used to measure how well Idorsia manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| G Lutz | VAT Group AG | N/A | |
| Gnther Metz | Santhera Pharmaceuticals Holdin | 65 | |
| Rahma Samow | Straumann Holding AG | 44 | |
| J Haggerty | VAT Group AG | N/A | |
| J Zoller | VAT Group AG | N/A | |
| Adesh Kaul | Basilea Pharmaceutica AG | 49 | |
| Fabian Chiozza | VAT Group AG | 42 | |
| Dario Eklund | Santhera Pharmaceuticals Holdin | 55 | |
| Sanna Fowler | Lonza Group AG | N/A | |
| Marc MD | Basilea Pharmaceutica AG | 59 | |
| M Zickar | VAT Group AG | N/A | |
| Caroline MD | Lonza Group AG | 51 | |
| Laurenz Kellenberger | Basilea Pharmaceutica AG | 56 | |
| Philippe Deecke | Lonza Group AG | 51 | |
| Gerrit Hauck | Basilea Pharmaceutica AG | 59 | |
| Neville MD | Santhera Pharmaceuticals Holdin | N/A | |
| Dietrich Stber | Basilea Pharmaceutica AG | N/A | |
| Dirk Oehlers | Lonza Group AG | N/A | |
| Ursula Eberhardt | Basilea Pharmaceutica AG | 61 | |
| Wolfgang Becker | Straumann Holding AG | 57 | |
| Peer Schroder | Basilea Pharmaceutica AG | N/A | |
Management Performance
| Return On Equity | -64.61 | |||
| Return On Asset | -0.42 |
Idorsia Leadership Team
Elected by the shareholders, the Idorsia's board of directors comprises two types of representatives: Idorsia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Idorsia. The board's role is to monitor Idorsia's management team and ensure that shareholders' interests are well served. Idorsia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Idorsia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Simon Jose, Ex Officer | ||
| Andrew Weiss, Sr Communications | ||
| Olivier Lambert, Sr Assurance | ||
| Christoph Boss, VP Chemistry | ||
| Martine Clozel, Ex Officer | ||
| JeanPaul MD, CEO Director | ||
| Alexander Khatuntsev, VP HR | ||
| Andr Muller, Ex CFO | ||
| Julien LLM, Group VP | ||
| Guy MD, Ex Officer | ||
| Markus Riederer, VP Biology |
Idorsia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Idorsia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -64.61 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (8.25) % | |||
| Current Valuation | 2.88 B | |||
| Shares Outstanding | 187.56 M | |||
| Shares Owned By Insiders | 36.02 % | |||
| Shares Owned By Institutions | 23.03 % | |||
| Price To Book | 27.65 X | |||
| Price To Sales | 48.84 X | |||
| Revenue | 97.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Idorsia Stock Analysis
When running Idorsia's price analysis, check to measure Idorsia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Idorsia is operating at the current time. Most of Idorsia's value examination focuses on studying past and present price action to predict the probability of Idorsia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Idorsia's price. Additionally, you may evaluate how the addition of Idorsia to your portfolios can decrease your overall portfolio volatility.